These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22976135)

  • 1. Cilengitide treatment for malignant glioma: current status and future direction.
    Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
    Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting integrins in malignant glioma.
    Tabatabai G; Weller M; Nabors B; Picard M; Reardon D; Mikkelsen T; Ruegg C; Stupp R
    Target Oncol; 2010 Sep; 5(3):175-81. PubMed ID: 20820929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
    Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
    Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
    Scaringi C; Minniti G; Caporello P; Enrici RM
    Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of integrins in glioma biology and anti-glioma therapies.
    Tabatabai G; Tonn JC; Stupp R; Weller M
    Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
    Onishi M; Ichikawa T; Kurozumi K; Fujii K; Yoshida K; Inoue S; Michiue H; Chiocca EA; Kaur B; Date I
    Neuropathology; 2013 Apr; 33(2):162-74. PubMed ID: 22989076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
    Reardon DA; Nabors LB; Stupp R; Mikkelsen T
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1225-35. PubMed ID: 18616418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
    Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
    Reardon DA; Neyns B; Weller M; Tonn JC; Nabors LB; Stupp R
    Future Oncol; 2011 Mar; 7(3):339-54. PubMed ID: 21417900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
    Cai W; Chen X
    Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin control of the transforming growth factor-β pathway in glioblastoma.
    Roth P; Silginer M; Goodman SL; Hasenbach K; Thies S; Maurer G; Schraml P; Tabatabai G; Moch H; Tritschler I; Weller M
    Brain; 2013 Feb; 136(Pt 2):564-76. PubMed ID: 23378223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
    Yan C; Wang J; Yang Y; Ma W; Chen X
    J Cell Mol Med; 2019 Aug; 23(8):4876-4882. PubMed ID: 31210419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
    Gilbert MR; Kuhn J; Lamborn KR; Lieberman F; Wen PY; Mehta M; Cloughesy T; Lassman AB; Deangelis LM; Chang S; Prados M
    J Neurooncol; 2012 Jan; 106(1):147-53. PubMed ID: 21739168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Polo V; Farina M; Della Puppa A; Bertorelle R; Gardiman MP; Berti F; Zagonel V
    Anticancer Drugs; 2012 Aug; 23(7):749-53. PubMed ID: 22382388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
    Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
    J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of cellular adhesion and invasion in gliomas].
    Sasaki H; Yoshida K
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():68-73. PubMed ID: 16201502
    [No Abstract]   [Full Text] [Related]  

  • 20. Integrins: molecular targets in cancer therapy.
    Tucker GC
    Curr Oncol Rep; 2006 Mar; 8(2):96-103. PubMed ID: 16507218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.